ArticlePakistan journal of medical sciences2024
Clinical effects of debulking surgery combined with neoadjuvant chemotherapy in treating ovarian cancer and its influence on tumor markers and immune function.
Article in Pakistan journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does lymphadenectomy predict survival in early-stage epithelial ovarian cancer? An updated systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Article
- Positive Collaboration in Rehabilitation Nursing Enhances Fall Efficacy and Confidence in Elderly Patients with Cerebral Infarction.Therapeutics and clinical risk management · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Exploring the clinical efficacy of tumor cell reduction combined with neoadjuvant chemotherapy in treatment of ovarian cancer. Methods: Retrospective analysis was conducted of one hundred patients with advanced ovarian cancer at Yellow River Sanmenxia Hospital from January 2017 to December 2022. They were divided into control group and observation group based on treatment methods, with 50 cases in each group. The control group was treated with tumor cell reduction surgery, the observation group treated with neoadjuvant chemotherapy and tumor cell reduction surgery. The surgical related conditions, clinical treatment effects, tumor markers, cellular immune function levels, quality of life, and adverse reactions were compared. Results: The observation group had shorter surgical and hospitalization times, with less intraoperative blood loss and abdominal fluid accumulation compared to control group (P<0.05). The serum levels in both groups of patients were significantly reduced, and observation group had a higher degree of decrease (P<0.05). The levels of cellular immune function levels in both groups improved significantly, and observation group showed more significant improvement (P<0.05). The total efficacy of observation group patients was 72.00%, higher than control group's 52.00% (P<0.05). The SS-QOL scores of both groups of patients improved significantly, and the degree of improvement in observation group was significant (P<0.05). Conclusion: The combination of tumor cell reduction surgery and neoadjuvant chemotherapy for ovarian cancer can significantly shorten surgical and hospitalization time, inhibit tumor marker expression, improve patient immune function and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.